Canada · Health Canada Drug Product Database
BEXSERO
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 90167
- DIN
- 02417030
- Form
- Suspension
- Company as listed by source
- GLAXOSMITHKLINE INC
- Source status
- Marketed (2016-09-08)
- Source last updated
- 2026-02-10
Source-listed ingredients
- RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN — 50 MCG — per 0.5 ML
- RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN — 50 MCG — per 0.5 ML
- RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN — 50 MCG — per 0.5 ML
- OUTER MEMBRANE VESICLES (NEISSERIA MENINGITIDIS GROUP B NZ98/254 STRAIN) — 25 MCG — per 0.5 ML
These values do not establish equivalence or a dose recommendation.
Packages
- 1/10 Pfs
Source and coverage
Open Health Canada Drug Product Database →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse Canada records →